News & Events:SYRS

Check out this: Snap And 2 Other Stocks Insiders Are Selling Don't forget to check out our premarket coverage here .

Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. On the M&A front, Pfizer, Inc. announced a deal to buy migraine drugmaker Biohaven Pharmaceutical Holding Company Limited in a deal worth $11.6 billion.

Syros Pharmaceuticals Inc (SYRS): * SYROS PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE. * Q1 LOSS PER SHARE $0.40. * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2022 WERE $112.9 MILLION. * REVENUES WERE $5.5 MILLION FOR Q1 OF 2022.

  Syros Pharmaceuticals reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Syros Pharmaceuticals beat estimated earnings by 14.89%, reporting an EPS of $-0.4 versus an estimate of $-0.47. Revenue was up $640.00 thousand from the same period last year.

Three Data Readouts Expected in 2022: Data from the Safety Lead-ins of the SY-5609 Trial in Pancreatic Cancer and of the SELECT-AML-1 Phase 2 Trial; Data from the Dose Confirmation Study of SY-2101 in APL On Track to Report Data from Ongoing SELECT-MDS-1 Pivotal Trial in Q4 2023/Q1 2024 Management to Host Conference Call at 8:30 a.m. ET Today CAMBRIDGE, Mass.

  ** AcelRx Pharmaceuticals is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. ** Synthetic Biologics is likely to report earnings for its first quarter. ** Passage Bio is estimated to report earnings for its first quarter. ** Taysha Gene Therapies is expected to report earnings for its first quarter.

Syros Pharmaceuticals is set to give its latest quarterly earnings report on Monday, 2022-05-16. Analysts estimate that Syros Pharmaceuticals will report an earnings per share of $-0.47. Syros Pharmaceuticals bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update. To access the live conference call, please dial 595-4538 or 812-6496 and refer to conference ID 4664097.

66 Biggest Movers From Yesterday

Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit awards for an aggregate of 136,750 shares of Syros common stock to six newly hired employees in connection with their commencement of employment with Syros.

  During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

Syros Pharmaceuticals Inc  announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model. 

CDK12 Inhibitor Demonstrates Strong Anti-Tumor Activity as Single Agent and in Combination with a DNA Damaging Agent and a PARP Inhibitor in Models of Breast, Lung, and Ovarian Cancer On Track to Nominate CDK12 Inhibitor as Next Development Candidate in 2H 2022 CAMBRIDGE, Mass. “CDK12 is an attractive cancer target due to its role in transcription and DNA damage repair regulation.

Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

According to Benzinga Pro data, during Q4, Syros Pharmaceuticals posted sales of $7.80 million. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

  Syros Pharmaceuticals reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Syros Pharmaceuticals beat estimated earnings by 19.15%, reporting an EPS of $-0.38 versus an estimate of $-0.47. Revenue was up $2.10 million from the same period last year.

Here's a roundup of top developments in the biotech space over the last 24 hours: Anaptys Bio, Inc. said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints.